TOKYO— North Korea has lifted severe restrictions on foreign travel it imposed last year to keep the Ebola virus from crossing its borders. One tour company that takes tourists into North Korea, Uri Tours, said on its website Tuesday that it had been told by the country's national airline that the ban had been lifted. North Korea's decision to set the restrictions...» Read More
This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.
The New York Times reports on some of the hidden compromises in the final version of the Senate's health care reform bill.
If you have had the misfortune to follow this debate as it grinds through the Senate, several thoughts come to mind.
There is nothing in this bill that changes our views at Soleil regarding the health care stocks we have been recommending.
I went to the beleaguered Genzyme manufacturing plant in Allston, MA yesterday to get briefed on what exactly happened/is happening there for background ahead of my interview today with the CEO.
I'm on Amtrak's Acela (the faster train) to Boston to do an exclusive interview tomorrow with Genzyme Chairman and CEO Henri Termeer. It'll be live on "Power Lunch" around 1:30p ET. I was planning on spending the train trip reading up on GENZ, but I got easily sidetracked by the Auxilium news.
Health officials are recalling hundreds of thousands of doses of swine flu vaccine after tests indicated they may not be potent enough to protect against the virus.
At the UN's Climate Summit in Copenhagen there's a lot of talk about reducing CO2 emissions. Coincidentally, the Danish capital is headquarters to Novo Nordisk, whose CEO is setting an example about cutting down on greenhouse gases in the environment.
I've never been to San Antonio. I've heard great things about it, especially the downtown and the river that runs through it, but haven't been able to check it out yet.
Analyst meetings are usually carefully scripted, dry affairs. It's strictly business and rarely, if ever, does an exec open up and get personal. In the first q and a session at today's Lilly analyst meeting, John Johnson, the head of the company's cancer drug unit and former CEO of ImClone, fielded a question about Erbitux.
On May 8th Dendreon announced an offering of nearly 11 million more shares. Seven months later, on December 8th, DNDN announced another offering, this time for 15 million shares.
I don't often write about micro caps, but given that the broader topic is bioterrorism and specifically something that the whole country was on pins and needles about not too long ago, I'm making an exception.
Monday will be a big day for the biotechnology company Celgene. At 3:45p ET, the embargo will apparently lift on new data for its drug Revlimid in an earlier stage of the blood cancer known as multiple myeloma.
Normally things tend to slow down a bit between Thanksgiving and New Year's Day. But this week alone we've already seen two biopharma partnership deals in as many days. First Pfizer and Protalix and now AstraZeneca and Targacept.
Pfizer today announced it's paying what amounts to chump change (a total of $115 million over time) for the rights to a biotech drug to treat a rare disease. And as I write this, investors are rewarding the world's biggest drug company by making its stock the biggest percentage gainer among the Dow 30.
Genzyme, the biotechnology company already reeling from problems manufacturing its drugs for rare diseases, will soon have a formidable new competitor — the pharmaceutical giant Pfizer.
For the second time in three weeks I'm at a flu vaccine manufacturing plant today. Construction isn't finished on the Novartis site yet, but nonetheless they're doing the formal ribbon-cutting ceremony here in Holly Springs, NC this afternoon.
Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.
VVUS this morning unveiled positive late-stage test results on the ED pill. The company touts that it takes effect in less than 30 minutes and it's out of your system within six hours or so.
When I do an interview with a clinical trial investigator I typically try to take care of what I call the "housekeeping" at the beginning or end.